Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells $131,753.52 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of CeriBell stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $26.96, for a total transaction of $131,753.52. Following the completion of the transaction, the chief technology officer directly owned 203,118 shares in the company, valued at approximately $5,476,061.28. The trade was a 2.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Raymond Woo also recently made the following trade(s):

• On Thursday, October 1st, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.38, for a total transaction of $119,145.06.
• On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.33, for a total value of $118,900.71.
• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total value of $47,535.58.

CeriBell Trading Up 2.2%

NASDAQ:CBLL opened at $26.59 on Friday. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -13.71 and a beta of 0.86. The stock has a fifty day simple moving average of $25.25 and a 200 day simple moving average of $20.92. CeriBell, Inc. has a 1-year low of $11.27 and a 1-year high of $28.89.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). The firm had revenue of $29.34 million during the quarter, compared to analyst estimates of $29.18 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Sell-side analysts forecast that CeriBell, Inc. will post -2.03 earnings per share for the current year.

Institutional Trading of CeriBell

A number of hedge funds and other institutional investors have recently modified their holdings of CBLL. Strs Ohio acquired a new position in CeriBell during the 1st quarter worth approximately $27,000. Legal & General Group Plc purchased a new stake in shares of CeriBell during the second quarter valued at about $53,000. State of Wyoming acquired a new stake in CeriBell during the 1st quarter worth $62,000. Quantbot Technologies LP acquired a new stake in CeriBell during the second quarter worth approximately $112,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in CeriBell in the 1st quarter valued at about $341,000.

Analysts Set New Price Targets

Several equities analysts recently commented on CBLL shares. Canaccord Genuity Group raised their target price on CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. Raymond James Financial reiterated a “strong-buy” rating and issued a $29.00 target price on shares of CeriBell in a research note on Thursday, September 3rd. TD Cowen boosted their target price on shares of CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Finally, BTIG Research restated a “buy” rating on shares of CeriBell in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $31.25.

About CeriBell

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.